Search Our Scientific Publications & Authors

Clin Cancer Res 2021 Feb 26. Epub 2021 Feb 26.

Developmental Therapeutics, Massachusetts General Hospital Cancer Center.

Purpose: Preclinical and clinical data suggest that downstream inhibition with a MEK inhibitor, such as binimetinib, might be efficacious for -mutated cancers.

Patients And Methods: Patients enrolled in the NCI-MATCH trial master protocol underwent tumor biopsy and molecular profiling by targeted next-generation sequencing. Patients with -mutated tumors, except melanoma, were enrolled in subprotocol Z1A, a single-arm study evaluating binimetinib 45 mg twice daily. Read More

J Dermatol 2021 Feb 18. Epub 2021 Feb 18.

Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.

The combination of BRAF inhibitor and MEK inhibitor is one of the first-line treatments for unresectable BRAF-mutant melanoma or as an adjuvant therapy. However, some patients who received the combination of dabrafenib and trametinib (CombiDT) or the combination of encorafenib and binimetinib (CombiEB) had adverse events (AEs) including pyrexia. We herein report a patient with BRAF-mutated melanoma who repeatedly developed elevated levels of D-dimer and pyrexia after CombiDT and CombiEB treatments. Read More

Anticancer Drugs 2021 Feb 9. Epub 2021 Feb 9.

Department of Clinical Pharmacy Department of Internal Medicine, Medisch Spectrum Twente, Enschede, the Netherlands.

Introduction: Encorafenib (Braftovi) is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation, in combination with binimetinib (Mektovi). According to the product label of encorafenib, there are no specific treatment recommendations in case of an overdose.

Case Presentation: We report on a 63-year-old man who ingested a double dose (900 mg) of encorafenib for 16 days. Read More

Adv Ther 2021 Feb 10. Epub 2021 Feb 10.

Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.

Introduction: Recently the phase 3 BEACON trial showed that the combination of encorafenib, cetuximab, and binimetinib versus cetuximab and irinotecan/FOLFIRI improved overall survival in pre-treated patients with metastatic colorectal cancer (mCRC) with BRAF V600E mutation. However, whether the benefits of these therapies justify their high costs has not been estimated in the USA. The purpose of this study was to evaluate the cost-effectiveness of BEC (binimetinib, encorafenib, and cetuximab), EC (encorafenib and cetuximab), and CI/CF (cetuximab with irinotecan or FOLFIRI) in patients with BRAF V600E-mutated mCRC after first- and second-line therapy. Read More

ESMO Open 2021 Feb 5;6(2):100050. Epub 2021 Feb 5.

Medical Oncology, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.

Background: Approved first-line treatments for patients with BRAF V600-mutant advanced melanoma include nivolumab (a programmed cell death protein 1 inhibitor) plus ipilimumab (a cytotoxic T lymphocyte antigen-4 inhibitor; NIVO+IPI) and the BRAF/MEK inhibitors dabrafenib plus trametinib (DAB+TRAM), encorafenib plus binimetinib (ENCO+BINI), and vemurafenib plus cobimetinib (VEM+COBI). Results from prospective randomized clinical trials (RCTs) comparing these treatments have not yet been reported. This analysis evaluated the relative efficacy and safety of NIVO+IPI versus DAB+TRAM, ENCO+BINI, and VEM+COBI in patients with BRAF-mutant advanced melanoma using a matching-adjusted indirect comparison (MAIC). Read More